Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
IPO Year: 2021
Exchange: NASDAQ
Website: unicycive.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/21/2025 | $6.00 | Buy | Guggenheim |
4/4/2024 | $9.00 | Overweight | Piper Sandler |
8/9/2021 | $13.50 | Buy | Roth Capital |